Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Use of Whole-Exome Sequencing and Pedigree Analysis to Identify X-linked Hypophosphatemia in Saudi Arabian Families.
J Endocr Soc
November 2024
College of Medicine, Alfaisal University, Riyadh, 11211, Saudi Arabia.
Context: X-linked hypophosphatemia (XLH) is the most common form of inherited hypophosphatemic rickets (HR), caused by pathogenic variants in the gene. Genetic diagnosis of XLH facilitates early treatment optimization, especially for patients suitable for burosumab, a recombinant anti-fibroblast growth factor-23 monoclonal antibody.
Objective: This study aimed to use whole-exome sequencing (WES) and pedigree analysis to identify patients with XLH.
Phase I Study of Simlukafusp Alfa (FAP-IL2v) with or without Atezolizumab in Japanese Patients with Advanced Solid Tumors.
Cancer Res Commun
September 2024
Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan.
Purpose: The aim of the study was to evaluate the safety/tolerability and pharmacokinetics of simlukafusp alfa (FAP-IL2v), an immunocytokine containing an anti-fibroblast activation protein-α (FAP) antibody and an IL2 variant, administered alone or with the PDL1 inhibitor atezolizumab, in Japanese patients with advanced solid tumors.
Patients And Methods: In this phase 1, open-label, dose-escalation study, patients received i.v.
Generic semi-automated radiofluorination strategy for single domain antibodies: [F]FB-labelled single domain antibodies for PET imaging of fibroblast activation protein-α or folate receptor-α overexpression in cancer.
EJNMMI Radiopharm Chem
July 2024
Molecular Imaging and Therapy Research Group (MITH), Vrije Universiteit Brussel (VUB), Laarbeeklaan 103. Building K., 1090, Brussels, Belgium.
Background: Radiofluorination of single domain antibodies (sdAbs) via N-succinimidyl-4-[F]fluorobenzoate ([F]SFB) has shown to be a promising strategy in the development of sdAb-based PET tracers. While automation of the prosthetic group (PG) [F]SFB production, has been successfully reported, no practical method for large scale sdAb labelling has been reported. Therefore, we optimized and automated the PG production, enabling a subsequently efficient manual conjugation reaction to an anti-fibroblast activation protein (FAP)-α sdAb (4AH29) and an anti-folate receptor (FR)-α sdAb (2BD42).
View Article and Find Full Text PDFHow Immunotherapy Has Redefined the Treatment Paradigm of Metastatic or Locally Advanced Muscle-Invasive Urothelial Bladder Carcinoma.
Cancers (Basel)
May 2024
Medical Oncology Department, Hôpital Saint André, University Hospital of Bordeaux, 33076 Bordeaux, France.
Article Synopsis
- In the last ten years, new treatments for advanced bladder cancer have been made, including special drugs that help the immune system fight cancer and other combined therapies.
- Two important studies showed that using combinations of these drugs with chemotherapy can help patients live longer.
- In 2024, doctors are looking at how these new treatments can be used together or alone to manage bladder cancer better, including some new ideas for using them early in treatment.
Near-infrared Photoimmunotherapy Targeting Cancer-Associated Fibroblasts in Patient-Derived Xenografts Using a Humanized Anti-Fibroblast Activation Protein Antibody.
Mol Cancer Ther
July 2024
Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Density, and Pharmaceutical Science, Okayama, Japan.
Esophageal cancer remains a highly aggressive malignancy with a poor prognosis, despite ongoing advancements in treatments such as immunotherapy. The tumor microenvironment, particularly cancer-associated fibroblasts (CAF), plays a crucial role in driving the aggressiveness of esophageal cancer. In a previous study utilizing human-derived xenograft models, we successfully developed a novel cancer treatment that targeted CAFs with near-infrared photoimmunotherapy (NIR-PIT), as an adjuvant therapy.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!